explore -WSS

explore

author：Wikipedia 2025-09-27 21:27:38 - browse：1949

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： After sickle

WSS

Hospitals consider fixing cancer drug shortages on their own

Supreme Court wrestles with OxyContin maker's bankruptcy deal

In diabetes hearing, Sanders takes on a new foe: food makers

FDA panel endorses Alnylam’s heart drug — after picking it apart

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Food makers to regulators: Ultra

focus

explore

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

SCOTUS to consider access to abortion pill mifepristone

United colonoscopy coverage change 'may cost lives,' doctors say

FDA needs staff influx to meet gene therapy needs, Marks says

Duchenne breakthrough therapy leaves behind pioneering families

After sickle

Supreme Court strikes down use of affirmative action

Leukemia patients are helped by Syndax's new type of therapy

In age of alternative facts, a scholarly course on calling out crap

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

focus

PEPFAR is under serious threat — and so is global health

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Diverse clinical trials: Why aren’t we there yet?

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Regeneron agrees to White House price limits on anti

CMS should re

Wikipedia

knowledge

focus

focus